All News
Filter News
Found 808,690 articles
-
Junshi Biosciences and Coherus Announce U.S. FDA Breakthrough Therapy Designation Granted for Toripalimab for 1st Line Treatment of Nasopharyngeal Carcinoma
8/12/2021
Shanghai Junshi Biosciences Co., Ltd and Coherus BioSciences, Inc. today announced that the United States Food and Drug Administration (“FDA”) has recently granted Breakthrough Therapy Designation (“BTD”) for toripalimab in combination with chemotherapy (gemcitabine and cisplatin) for the 1 st line treatment of recurrent or metastatic nasopharyngeal carcinoma.
-
Celsion Corporation Reports Second Quarter 2021 Financial Results and Provides Business Update
8/12/2021
Celsion Corporation today announced financial results for the three and six months ended June 30, 2021, and provided an update on clinical trial.
-
MIMEDX Promotes Marion Snyder to Chief of Staff, Senior Vice President, Government Affairs
8/12/2021
MiMedx Group, Inc. today announced the promotion of Marion Snyder to Chief of Staff, Senior Vice President, Government Affairs.
-
Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults
8/12/2021
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved Xywav ® oral solution for the treatment of idiopathic hypersomnia in adults.
-
Adial Pharmaceuticals Schedules Conference Call to Provide Clinical Update and Discuss Positive Business Developments
8/12/2021
Adial Pharmaceuticals, Inc. today announced it will host a conference call at 11:00 A.M. Eastern Time on Friday, August 20, 2021 to provide a clinical update and discuss the latest business developments.
-
PhaseBio Reports Second-Quarter 2021 Financial Results and Recent Business Highlights
8/12/2021
PhaseBio Pharmaceuticals, Inc. today provided an update on corporate activities and reported second-quarter 2021 financial results.
-
Sen-Jam Pharmaceutical Partners With Duke-NUS Medical School for a Phase 2 Trial for a New COVID 19 Treatment
8/12/2021
Sen-Jam, a life-science startup led by Registered Pharmacist Jacqueline Iversen, has partnered with researcher Ashley St. John PhD of the Duke-NUS Medical School in Singapore, to trial a novel combination of two proven drug molecules that may work pre-emptively to stop the progression of COVID to the Severe Acute Respiratory Syndrome (SARS) stage.
-
9 Meters Biopharma Provides Business Update and Reports Financial Results for the Second Quarter 2021
8/12/2021
9 Meters Biopharma, Inc. today provided an overview of its recent achievements and reported financial results for the second quarter ended June 30, 2021.
-
Pressure BioSciences New Eco-Friendly Agrochem Subsidiary Receives Over $1,000,000 in Orders in First Month of Operations
8/12/2021
Pressure BioSciences, Inc. today announced that its newly-formed agrochemicals subsidiary - PBI Agrochem, Inc. - has received initial purchase orders for over $1M of eco-friendly agrochemical products for delivery in 2021.
-
Mustang Bio Collaborates with Mayo Clinic on Novel CAR T Technology
8/12/2021
Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), today announced that the company has executed an exclusive license agreement with Mayo Clinic for a novel technology that may be able to transform the administration of chimeric antigen receptor engineered T cell (“CAR T”) therapies and potentially be used as an off-the-shelf therapy.
-
FDA Grants First of its Kind Indication for Chronic Sleep Disorder Treatment
8/12/2021
The U.S. Food and Drug Administration today approved a new indication for Xywav for idiopathic hypersomnia (IH) in adults.
-
Lynk Pharmaceuticals Announced First Patient Dosed in Phase I Clinical Study of Its Triple-Kinase Inhibitor LNK01002
8/12/2021
Lynk Pharmaceuticals Co., Ltd. , announced today that it has administered its triple-kinase inhibitor LNK01002 to the first patient in a phase I clinical trial.
-
Black Diamond Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
8/12/2021
Black Diamond Therapeutics, Inc. today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.
-
Viracta Therapeutics Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
8/12/2021
Viracta Therapeutics, Inc. today announced financial results for the second quarter of 2021 and provided clinical and corporate updates.
-
Moleculin Reports Second Quarter 2021 Financial Results and Provides Programs Update
8/12/2021
Moleculin Biotech, Inc. today announced its financial results for the quarter ended June 30, 2021.
-
DiaCarta Receives CE/IVD for its New COVID 19 test that Identifies Delta Plus and New Variants
8/12/2021
DiaCarta Inc. today announced that its new QuantiVirus™ SARS-CoV-2 Variant Detection Test received the CE/IVD marking and therefore, can now be commercialized within the EU and rest of the world.
-
AlzeCure to Present Abstract at ECNP Conference on NeuroRestore Project's Potential in Depression
8/12/2021
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced that an abstract about the neurology platform NeuroRestore, its link to BDNF/TrkB signalling and potential therapeutic role in depression, has been accepted for presentation at the ECNP 2021 conference.
-
Anebulo Pharmaceuticals Announces Formation of Scientific Advisory Board, Names First Two Members
8/12/2021
Anebulo Pharmaceuticals, Inc. today announced the formation of a Scientific Advisory Board (SAB) to advise on the Company’s clinical development programs and its product pipeline.
-
Government of Canada funds research on responding to possible adverse events following COVID-19 vaccination
8/12/2021
In the fight against COVID-19, it is critical that as many Canadians as possible get vaccinated. That is why the federal government is taking action to make sure every Canadian who wants a vaccine can get one.
-
Tenax Announces New Publication Highlighting Novel Levosimendan Mechanism of Action in Pulmonary Hypertension Patients with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)
8/12/2021
Tenax Therapeutics, Inc. today announced a new publication that identifies a novel mechanism of action behind the improved cardiovascular hemodynamics and exercise tolerance that was reported in the recent Phase 2 HELP Study (Burkhoff et al., JACC Heart Failure 2021; 9:360-70).